Palbociclib - Pfizer

Drug Profile

Palbociclib - Pfizer

Alternative Names: Ibrance; Iburance; Parvociclib; PD-0332991; PD-332991; PD-991; PF-332991

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onyx Pharmaceuticals; Pfizer
  • Developer Assistance Publique Hopitaux de Paris; Bergonie Institute; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; Georgetown University; German Breast Group; GlaxoSmithKline; Grupo Espanol de Tumores Neuroendocrinos; iOMEDICO AG; Karolinska Institute; National Cancer Institute (USA); Netherlands Cancer Institute; Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Brain metastases; Colorectal cancer; Gastrointestinal stromal tumours; Head and neck cancer; Pancreatic cancer; Prostate cancer; Urogenital cancer
  • Phase I/II Cancer; Malignant melanoma
  • Phase I Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • No development reported Glioblastoma; Mantle-cell lymphoma; Multiple myeloma

Most Recent Events

  • 05 Oct 2018 Pfizer collaborates with Calithera Biosciences to conduct clinical trials with CB 839, palbociclib and talazoparib
  • 01 Oct 2018 Emory University and Pfizer plan the phase II ASPIRE trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT03691493)
  • 25 Jun 2018 Efficacy and adverse events data from the phase III PALOMA trial in Breast cancer released by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top